M
Malcolm J. Moore
Researcher at Princess Margaret Cancer Centre
Publications - 238
Citations - 45832
Malcolm J. Moore is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Gemcitabine & Cancer. The author has an hindex of 64, co-authored 231 publications receiving 42222 citations. Previous affiliations of Malcolm J. Moore include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
A novel biomarker panel examining response to gemcitabine (G) with or without erlotinib (E) for pancreatic cancer (PA) therapy in NCIC clinical trials group PA.3.
David B. Shultz,Jonathan S. Pai,Madeline Sydney Graber,Gregory M. Heestand,Daniel T. Chang,Wendy R. Parulekar,Dongsheng Tu,Malcolm J. Moore,Albert C. Koong +8 more
TL;DR: A randomized control trial that demonstrated an overall survival (OS) benefit in patients receiving E in addition to G for local G during the second trimester of cancer treatment is described.
Journal ArticleDOI
When the goal is not cure: A randomized trial of a patient decision aid in advanced colorectal cancer
Natasha B. Leighl,Heather L. Shepherd,Phyllis Butow,Stephen Clarke,Margaret McJannett,Philip Beale,Nicholas Wilcken,Malcolm J. Moore,Eric X. Chen,Martin H.N. Tattersall,David Goldstein +10 more
TL;DR: A decision aid (DA) for decision-making in advanced cancer patients is developed that helps patients make informed decisions about treatment and supportive care decisions.
Journal ArticleDOI
Reply to D.J. Stewart
Journal ArticleDOI
Significance of baseline quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3.
Michael M. Vickers,Dongsheng Tu,Chee Lee,Paul Wheatley-Price,Wendy R. Parulekar,Michael Brundage,Malcolm J. Moore,Heather-Jane Au,Christopher J. O'Callaghan,Derek J. Jonker,Jolie Ringash,David Goldstein +11 more
TL;DR: There is insufficient information regarding the prognostic significance of baseline Quality of life (QoL) scores on overall survival (OS) and adverse events (AEs) in advanced pancreatic cancer.
Journal ArticleDOI
Cardiovascular disease (CVD) risk factors among cisplatin-treated testicular cancer survivors (TCS): A multicenter clinical study of U.S. and Canadian patients.
Chunkit Fung,Darren R. Feldman,Robert J. Hamilton,Somer Case-Eads,David J. Vaughn,Clair J. Beard,Malcolm J. Moore,Deepak M. Sahasrabudhe,Mary J. Brames,Sophie D. Fosså,Howard D. Sesso,Lawrence H. Einhorn,Lois B. Travis +12 more
TL;DR: Examination of CVD risk factors in an ongoing multi-center clinical study of TCS given modern cisplatin-based chemotherapy (CHEM) at centers in North America found patients were largely white, married, and had ful...